litlas
Log inCreate account

Jin Seok Ahn

Active 1993–2025

Also published as
Jin‐Seok Ahn · Jin-Seok Ahn
167
Papers
20,053
Citations
78
h-index
158
i10-index

Citations

Citations per year for Jin Seok Ahn1993: 1 citations1995: 1 citations1996: 1 citations1997: 2 citations1998: 1 citations1999: 1 citations2000: 3 citations2001: 2 citations2003: 1 citations2004: 3 citations2005: 1 citations2006: 4 citations2007: 3 citations2008: 5 citations2009: 13 citations2010: 11 citations2011: 29 citations2012: 35 citations2013: 76 citations2014: 77 citations2015: 89 citations2016: 118 citations2017: 133 citations2018: 190 citations2019: 611 citations2020: 894 citations2021: 1,015 citations2022: 842 citations2023: 707 citations2024: 1,274 citations2025: 680 citations2026: 23 citations1994: no citations, so this year is not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,087 citing papers, 20% of this breakdownChina: 1,823 citing papers, 17.4% of this breakdownItaly: 596 citing papers, 5.7% of this breakdownSouth Korea: 531 citing papers, 5.1% of this breakdownUnited Kingdom: 470 citing papers, 4.5% of this breakdownJapan: 466 citing papers, 4.5% of this breakdownFrance: 423 citing papers, 4% of this breakdownGermany: 398 citing papers, 3.8% of this breakdownSpain: 358 citing papers, 3.4% of this breakdownCanada: 305 citing papers, 2.9% of this breakdownSwitzerland: 243 citing papers, 2.3% of this breakdownNetherlands: 233 citing papers, 2.2% of this breakdown
0%20%Other 24.2%

Institutions

Fields

  • Medicine73.6%
  • Biochemistry, Genetics and Molecular Biology18.2%
  • Immunology and Microbiology4.1%
  • Computer Science1.1%
  • Engineering1%
  • Chemistry0.4%
  • Other1.6%

Topics

  • Lung Cancer Treatments and Mutations13.6%
  • Cancer Immunotherapy and Biomarkers8.6%
  • Lung Cancer Research Studies7.9%
  • Cancer Genomics and Diagnostics4.9%
  • Lung Cancer Diagnosis and Treatment4.9%
  • Brain Metastases and Treatment2.2%
  • Other57.9%

Coauthors

All papers

Open in search
  1. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma

    Authors: Nayoung Kim, Hong Kwan Kim, Kyungjong Lee, Yourae Hong, Jong Ho Cho, Jung Won Choi, Jung-Il Lee, Yeon‐Lim Suh, Bo Mi Ku, Hye Hyeon Eum, Soyean Choi, Yoon‐La Choi, Je‐Gun Joung, Woong‐Yang Park, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn, Hae‐Ock Lee - Nature Communications 2020 cited by 1,337

  2. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Authors: Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn, Dong‐Wan Kim, Sai‐Hong Ignatius Ou, M. Pérol, Rafał Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noé, Peter N. Morcos, Tony Mok - New England Journal of Medicine 2017 cited by 2,455

  3. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

    Authors: Hyunchul Jung, Hong Sook Kim, Jeong Yeon Kim, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Manel Esteller, Se‐Hoon Lee, Jung Kyoon Choi - Nature Communications 2019 cited by 563

  4. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

    Authors: Tony Mok, D. Ross Camidge, Shirish M. Gadgeel, Rafael Rosell, Rafał Dziadziuszko, D.-W. Kim, M. Pérol, S.-H.I. Ou, Jin Seok Ahn, A. Shaw, Walter Bordogna, Vlatka Smoljanović, Magalie Hilton, Thorsten Ruf, Johannes Noé, Solange Peters - Annals of Oncology 2020 cited by 686

  5. Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer

    Authors: Sehhoon Park, Chan‐Young Ock, Hyojin Kim, Sérgio Pereira, Seonwook Park, Minuk Ma, Sangjoon Choi, Seokhwi Kim, Seunghwan Shin, Brian Jaehong Aum, Kyunghyun Paeng, Donggeun Yoo, Hongui Cha, Sunyoung Park, Koung Jin Suh, Hyun Ae Jung, Se Hyun Kim, Yu Jung Kim, Jong‐Mu Sun, Jin-Haeng Chung, Jin Seok Ahn, Myung‐Ju Ahn, Jong Seok Lee, Keunchil Park, Sang Yong Song, Yung‐Jue Bang, Yoon‐La Choi, Tony Mok, Se‐Hoon Lee - Journal of Clinical Oncology 2022 cited by 282

  6. Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer

    Authors: Yi‐Long Wu, Rafał Dziadziuszko, Jin Seok Ahn, Fabrice Barlési, Makoto Nishio, Ki Hyeong Lee, Jong Seok Lee, Wen‐Zhao Zhong, Hidehito Horinouchi, Weimin Mao, Maximilian J. Hochmair, Filippo de Marinis, M.R. Migliorino, Igor Bondarenko, Shun Lü, Qun Wang, Tania Ochi Lohmann, Tingting Xu, Andrés F. Cardona, Thorsten Ruf, Johannes Noé, Benjamin Solomon - New England Journal of Medicine 2024 cited by 382

  7. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Rearranged or Translocated Non–Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)

    Authors: Sehhoon Park, Tae Min Kim, Ji‐Youn Han, Gyeong‐Won Lee, Byoung Yong Shim, Yun‐Gyoo Lee, Sang‐We Kim, Il Hwan Kim, Suee Lee, Yu Jung Kim, Ji Hyun Park, Sang-Gon Park, Ki Hyeong Lee, Eun Joo Kang, Ju Won Kim, Seong Hoon Shin, Chan‐Young Ock, Byung‐Ho Nam, Jaebong Lee, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn - Journal of Clinical Oncology 2023 cited by 164

  8. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

    Authors: James Chih‐Hsin Yang, Sang-We Kim, Dong‐Wan Kim, Jong Seok Lee, Byoung Chul Cho, Jin-Seok Ahn, Dae H. Lee, Tae Min Kim, Jonathan W. Goldman, Ronald B. Natale, Andy Brown, Barbara Collins, Juliann Chmielecki, Karthick Vishwanathan, Ariadna Mendoza‐Naranjo, Myung‐Ju Ahn - Journal of Clinical Oncology 2019 cited by 397

  9. LBA2 ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)

    Authors: Benjamin Solomon, Jin Seok Ahn, Rafał Dziadziuszko, Fabrice Barlési, Makoto Nishio, Daniel Lee, Jin Sun Lee, W-Z. Zhong, Hidehito Horinouchi, Weimin Mao, Maximilian J. Hochmair, Filippo de Marinis, M.R. Migliorino, Igor Bondarenko, Tania Ochi Lohmann, Tao Xu, A. Cardona Gavaldon, Walter Bordogna, Thorsten Ruf, Yi‐Long Wu - Annals of Oncology 2023 cited by 71

  10. The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors

    Authors: Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su‐Hyung Park, Keunchil Park, Myung‐Ju Ahn, Eui‐Cheol Shin - Clinical Cancer Research 2019 cited by 212

  11. Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

    Authors: Jang Ho Cho, Sung Hee Lim, Ho Jung An, Ki Hwan Kim, Keon Uk Park, Eun Joo Kang, Yoon Hee Choi, Mi Sun Ahn, Myung Hee Lee, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn - Journal of Clinical Oncology 2019 cited by 359

  12. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non–Small Cell Lung Cancer

    Authors: Sun Min Lim, Toshio Fujino, Chulwon Kim, Gwanghee Lee, Yong-Hee Lee, Dong‐Wan Kim, Jin Seok Ahn, Tetsuya Mitsudomi, Taiguang Jin, Sang-Yoon Lee - Clinical Cancer Research 2023 cited by 72

  13. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

    Authors: Seo‐Young Park, M.-H. Lee, Minjung Seong, S.T. Kim, Jin Hyoung Kang, Byoung Chul Cho, K.H. Lee, E.K. Cho, Jong‐Mu Sun, S.-H. Lee, Jin Seok Ahn, K. Park, Myung‐Ju Ahn - Annals of Oncology 2020 cited by 192

  14. Regulatory (FoxP3+) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer

    Authors: Jiae Koh, Joon Young Hur, Kyoung Young Lee, Mi Soon Kim, Jae Yeong Heo, Bo Mi Ku, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn - Scientific Reports 2020 cited by 87

  15. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

    Authors: Joonho Shim, H.S. Kim, Hongui Cha, Soo‐Chan Kim, T.M. Kim, Valsamo Anagnostou, Yoon‐La Choi, Hyun Ae Jung, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, K. Park, W.-Y. Park, S.-H. Lee - Annals of Oncology 2020 cited by 149

  16. Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

    Authors: Jinhyun Cho, Hae Su Kim, Bo Mi Ku, Yoon‐La Choi, Răzvan Cristescu, Joungho Han, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn - Journal of Clinical Oncology 2018 cited by 343

  17. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures

    Authors: Zhengyan Kan, Ying Ding, Jin-Ho Kim, Hae Hyun Jung, Woosung Chung, Samir Lal, Soonweng Cho, Julio Fernandez-Banet, Se Kyung Lee, Seok Won Kim, Jeong Eon Lee, Yoon‐La Choi, Shibing Deng, Ji‐Yeon Kim, Jin Seok Ahn, Ying Sha, Xinmeng Jasmine Mu, Jae‐Yong Nam, Young‐Hyuck Im, Soo Hyun Lee, Woong‐Yang Park, Seok Jin Nam, Yeon Hee Park - Nature Communications 2018 cited by 210

  18. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1–2 study

    Authors: Myung‐Ju Ahn, Ji‐Youn Han, Ki Hyeong Lee, Sang-We Kim, Dong‐Wan Kim, Yun‐Gyoo Lee, Eun Kyung Cho, Joo-Hang Kim, Gyeong‐Won Lee, Jong Seok Lee, Young Joo Min, Jin-Soo Kim, Sung Sook Lee, Hye Ryun Kim, Min Hee Hong, Jin Seok Ahn, Jong‐Mu Sun, Heung Tae Kim, Ki Hyeong Lee, Sohee Kim, Byoung Chul Cho - The Lancet Oncology 2019 cited by 135

  19. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors

    Authors: Byoung Chul Cho, Ji‐Youn Han, Sang‐We Kim, Ki Hyeong Lee, Eun Kyung Cho, Yun‐Gyoo Lee, Dong‐Wan Kim, Joo-Hang Kim, Gyeong‐Won Lee, Jong-Seok Lee, Byoung Yong Shim, Jin-Soo Kim, Sang Hoon Chun, Sung Sook Lee, Hye Ryun Kim, Min Hee Hong, Jin Seok Ahn, Jong‐Mu Sun, Youngjoo Lee, Ki Hyeong Lee, Ji Ah Kang, NaMi Lee, Mijung Kwon, Carin R. Espenschied, Arielle Yablonovitch, Myung‐Ju Ahn - Journal of Thoracic Oncology 2021 cited by 91

  20. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer

    Authors: Hyun Ae Jung, Bo Mi Ku, Yeon Jeong Kim, Sehhoon Park, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Jong Ho Cho, Hong Kwan Kim, Yong Soo Choi, Yoon‐La Choi, Sun Hye Shin, Byeong‐Ho Jeong, Sang‐Won Um, Hojoong Kim, Kyunga Kim, Myung‐Ju Ahn, Jingook Kim - Journal of Thoracic Oncology 2023 cited by 67

  21. Prevalence and detection of low-allele-fraction variants in clinical cancer samples

    Authors: Hyun‐Tae Shin, Yoon‐La Choi, Jae Won Yun, Nayoung K. D. Kim, Sook‐Young Kim, Hyo Jeong Jeon, Jae‐Yong Nam, Chung Lee, Daeun Ryu, Sang Cheol Kim, Kyunghee Park, Eunjin Lee, Joon Seol Bae, Dae Soon Son, Je‐Gun Joung, Jeeyun Lee, Seung Tae Kim, Myung‐Ju Ahn, Se‐Hoon Lee, Jin Seok Ahn, Woo Yong Lee, Bo Young Oh, Yeon Hee Park, Jeong Eon Lee, Kwang Hyuk Lee, Hee Cheol Kim, Kyoung‐Mee Kim, Young‐Hyuck Im, Keunchil Park, Peter J. Park, Woong‐Yang Park - Nature Communications 2017 cited by 198

  22. Five-Year Overall Survival and Prognostic Factors in Patients with Lung Cancer: Results from the Korean Association of Lung Cancer Registry (KALC-R) 2015

    Authors: Da Som Jeon, Ho Cheol Kim, Se Hee Kim, Tae Jung Kim, Hong Kwan Kim, Mi Hyung Moon, Kyongmin Sarah Beck, Yang-Gun Suh, Changhoon Song, Jin Seok Ahn, Jeong Eun Lee, Jeong Uk Lim, Jae Hyun Jeon, Kyu‐Won Jung, Chi Young Jung, Jeong Su Cho, Yoo Duk Choi, Seung-Sik Hwang, Chang‐Min Choi, Korea Central Cancer Registry - Cancer Research and Treatment 2022 cited by 99

  23. MDSC subtypes and CD39 expression on CD8 + T cells predict the efficacy of anti‐PD‐1 immunotherapy in patients with advanced NSCLC

    Authors: Jiae Koh, Youjin Kim, Kyoung Young Lee, Joon Young Hur, Mi Soon Kim, Boram Kim, Hee Jin Cho, Yeong Chan Lee, Yeon Hee Bae, Bo Mi Ku, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn - European Journal of Immunology 2020 cited by 90

  24. Development and Validation of Digital Health Technology Literacy Assessment Questionnaire

    Authors: Junghee Yoon, Mangyeong Lee, Jin Seok Ahn, Dongryul Oh, Soo-Yong Shin, Yoon Jung Chang, Juhee Cho - Journal of Medical Systems, J. Medical Syst. 2022 cited by 69